297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Similar Items

• 96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo
  by: Sara Brett, et al.
  Published: (2020-11-01)
• Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
  by: Alexandra Gyurdieva, et al.
  Published: (2022-09-01)
• 354 Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling
  by: Stefan Zajic, et al.
  Published: (2023-11-01)
• TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
  by: Alaa Alsalloum, et al.
  Published: (2023-10-01)
• LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
  by: Knuth A, et al.
  Published: (2004-07-01)